Cough in interstitial lung disease

被引:14
作者
Garner, Justin [1 ]
George, Peter M. [1 ,2 ]
Renzoni, Elisabetta [1 ,2 ]
机构
[1] Royal Brompton & Harefield NHS Trust, Interstitial Lung Dis Unit, London, England
[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England
关键词
Cough; Interstitial lung disease; Lung fibrosis; Mechanisms; IDIOPATHIC PULMONARY-FIBROSIS; MUC5B PROMOTER POLYMORPHISM; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; SYSTEMIC-SCLEROSIS; GASTROESOPHAGEAL-REFLUX; DOUBLE-BLIND; INCREASED EXPRESSION; INVOLVEMENT; PIRFENIDONE;
D O I
10.1016/j.pupt.2015.10.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cough in the context of interstitial lung disease (ILD) has not been the focus of many studies. However, chronic cough has a major impact on quality of life in a significant proportion of patients with ILD. For the purpose of this review, we have chosen to highlight some of the more frequently encountered diffuse lung diseases including idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis and systemic sclerosis associated ILD. Many of the underlying mechanisms remain speculative and further research is now required to elucidate the complex pathways involved in the pathogenesis of chronic cough in ILD. This will hopefully pave the way for the identification of new therapeutic agents to alleviate this distressing and often intractable symptom. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:122 / 128
页数:7
相关论文
共 129 条
[1]   P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study [J].
Abdulqawi, Rayid ;
Dockry, Rachel ;
Holt, Kimberley ;
Layton, Gary ;
McCarthy, Bruce G. ;
Ford, Anthony P. ;
Smith, Jaclyn A. .
LANCET, 2015, 385 (9974) :1198-1205
[2]   Sensory input to the central nervous system from the lungs and airways: A prominent role for purinergic signalling via P2X2/3 receptors [J].
Adriaensen, Dirk ;
Brouns, Inge ;
Timmermans, Jean-Pierre .
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2015, 191 :39-47
[3]  
Amin K., RESP MED, V95
[4]   Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].
Azuma, A ;
Nukiwa, T ;
Tsuboi, E ;
Suga, M ;
Abe, S ;
Nakata, K ;
Taguchi, Y ;
Nagai, S ;
Itoh, H ;
Ohi, M ;
Sato, A ;
Kudoh, S ;
Raghu, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047
[5]   Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment [J].
Azuma, Arata ;
Taguchi, Yoshio ;
Ogura, Takashi ;
Ebina, Masahito ;
Taniguchi, Hiroyuki ;
Kondoh, Yasuhiro ;
Suga, Moritaka ;
Takahashi, Hiroki ;
Nakata, Koichiro ;
Sato, Atsuhiko ;
Kudoh, Shoji ;
Nukiwa, Toshihiro .
RESPIRATORY RESEARCH, 2011, 12
[6]   Sensory neuropathic cough: A common and treatable cause of chronic cough [J].
Bastian, Robert W. ;
Vaidya, Abhay M. ;
Delsupehe, Kathelijne G. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2006, 135 (01) :17-21
[7]   Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy Comparison of Different Methods of Evaluation [J].
Baughman, Robert P. ;
Shipley, Ralph ;
Desai, Sujal ;
Drent, Marjolein ;
Judson, Marc A. ;
Costabel, Ulrich ;
du Bois, Roland M. ;
Kovuru, Mani ;
Schlenker-Herceg, Rozsa ;
Flavin, Susan ;
Lo, Kim Hung ;
Barnathan, Elliot S. .
CHEST, 2009, 136 (02) :526-535
[8]   Sarcoidosis [J].
Baughman, RP ;
Lower, EE ;
du Bois, RM .
LANCET, 2003, 361 (9363) :1111-1118
[9]   Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? [J].
Belkin, Amanda ;
Swigris, Jeffrey J. .
CURRENT OPINION IN PULMONARY MEDICINE, 2013, 19 (05) :474-479
[10]   COUGH AND ANGIOTENSIN CONVERTING ENZYME-INHIBITION [J].
BERKIN, KE ;
BALL, SG .
BMJ-BRITISH MEDICAL JOURNAL, 1988, 296 (6632) :1279-1280